Grace Therapeutics Inc (GRCE)

Apr 9, 2025, 8:00 AM EDT - 17 days ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Mar 11, 2025, 7:00 AM EDT - 6 weeks ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Feb 25, 2025, 8:00 AM EST - 2 months ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:00 AM EST - 2 months ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 10, 2025, 12:05 PM EST - 2 months ago

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Feb 10, 2025, 8:05 AM EST - 2 months ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:01 AM EST - 2 months ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Jan 7, 2025, 8:00 AM EST - 3 months ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Oct 25, 2024, 8:00 AM EDT - 6 months ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Sep 25, 2024, 7:30 AM EDT - 7 months ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 5, 2024, 10:35 AM EDT - 8 months ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:00 AM EDT - 9 months ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Jun 27, 2024, 4:05 PM EDT - 10 months ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 21, 2024, 8:00 AM EDT - 11 months ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

May 28, 2024, 4:05 PM EDT - 11 months ago

Acasti Pharma to Attend BIO International Convention 2024

Feb 12, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 1, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Dec 13, 2023, 8:00 AM EST - 1 year ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Nov 13, 2023, 8:00 AM EST - 1 year ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 4, 2023, 8:00 AM EDT - 1 year ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Aug 11, 2023, 7:00 AM EDT - 1 year ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 9, 2023, 4:05 PM EDT - 1 year ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Jul 10, 2023, 9:00 AM EDT - 1 year ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 7, 2023, 8:00 AM EDT - 1 year ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 5, 2023, 9:00 AM EDT - 1 year ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jun 23, 2023, 7:00 AM EDT - 2 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 22, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

May 17, 2023, 9:00 AM EDT - 2 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 8, 2023, 7:00 AM EDT - 2 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Apr 4, 2023, 8:01 AM EDT - 2 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Appointment of Prashant Kohli as CEO

Mar 30, 2023, 8:30 AM EDT - 2 years ago

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 8, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Feb 28, 2023, 1:00 PM EST - 2 years ago

Acasti Pharma Recognizes Rare Disease Day

Feb 14, 2023, 3:53 PM EST - 2 years ago

Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript

Feb 14, 2023, 7:00 AM EST - 2 years ago

Acasti Pharma Reports Third Quarter 2023 Operational Results

Feb 7, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

Jan 25, 2023, 9:00 AM EST - 2 years ago

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Jan 24, 2023, 4:15 PM EST - 2 years ago

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

Jan 17, 2023, 8:45 AM EST - 2 years ago

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Jan 13, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

Jan 5, 2023, 9:00 AM EST - 2 years ago

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Dec 28, 2022, 8:00 AM EST - 2 years ago

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

Nov 14, 2022, 11:23 PM EST - 2 years ago

Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript

Nov 14, 2022, 7:00 AM EST - 2 years ago

Acasti Pharma Reports Second Quarter 2023 Operational Results

Nov 9, 2022, 4:15 PM EST - 2 years ago

Acasti Pharma to Present at Q4 Investor Summit